PPT-Dolutegravir Containing

R egimens m ay Need O ptimization for Youth Failing ART V Kouamou J Manasa D Katzenstein A McGregor CE Ndhlovu A T Makadzange PESU Study Team C onflict of Interest D eclaration. David Spach, MD. Clinical Director, Northwest AETC. Professor of Medicine, Division of Infectious Diseases. University of Washington. Last Updated: October 21, 2013. 2013 . Asilomar. Update. New Occupational . New pricing agreement will speed up access to generic, dolutegravir (DTG)-based fixed dose combinations (FDCs) . HIV positive people in low- and middle-income countries including South Africa can be treated for around R900 (US $75 a year) . HIV Drug Resistance (HIVDR) and Antimicrobial Resistance (AMR): Science and Action. IAS 2017 . Paris . 24. th. July 2017. Modelling the cost and cost-effectiveness of responses to . HIV drug resistance. of HIV. . Convenience, tolerability, simplicity. New & Investigational Agents. “Quad” Pill- . Stribild. Released by FDA 08-27-12. Tenofovir Emtricitabine Cobicistat Elvitegravir. “Booster”. Dolutegravir monotherapy vs. dolutegravir/ abacavir / lamivudine for HIV-1-infected virologically suppressed patients: results from the randomized non- inferiority MONCAY trial L. Hocqueloux Joseph J. Eron, Jr, MD. Professor of Medicine. University of North Carolina. Chapel Hill, North Carolina. Panelists. Constance Benson. Hyman Scott. Annie . Luetkemeyer. Robert . Schooley. Financial Relationships With Commercial Entities. SWORD-1 . and SWORD-. 2. Dolutegravir plus Rilpivirine as Maintenance Dual Therapy. SWORD-1 and SWORD-2: Design. Source: . Llibre. JM, et al. Lancet. 2018;39:839-49.. Background. : . Identical, randomized, multinational, open-label, industry-sponsored, parallel-group, . Dovato. ). Last Updated: November 28, 2022. Prepared by:. Brian R. Wood, MD. David H. Spach, MD. Dolutegravir-Lamivudine. Photograph courtesy of . ViiV. INSTI. NRTI. 50 mg. 300 mg. Dolutegravir-Lamivudine. –. NAIVE ADULTS WITH HIV-1 INFECTION: 96-WEEK RESULTS FROM THE GEMINI STUDIES. 1. Fundación Huesped, Buenos Aires, Argentina; . 2. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; . FLAMINGO. Dolutegravir + 2 NRTIs versus Darunavir + RTV + 2 NRTIs . FLAMINGO: Study Design. Source: . Clotet. B, et al. . Lancet. 2014;383:2222-31. . Dolutegravir + . TDF-FTC or ABC-3TC. (n = 242). Darunavir + Ritonavir + . SPRING-2 Study. Dolutegravir. versus Raltegravir. SPRING-2: Design. Source: . Raffi. F, et al. Lancet. 2013;381:735-43.. Dolutegravir. : 50 mg QD. Fixed-dose NRTI backbone*. (n = 411). Raltegravir. Prepared by:. Brian R. Wood, MD. David H. Spach, MD. Last Updated: January 28, 2021. Dolutegravir (. Tivicay. ) . INSTI. Tivicay. . [TIV-eh-kay]. Dolutegravir. Treatment Naïve. : 50 mg once daily with or without food. Judith S. Currier, MD, MSc. Professor of Medicine. University of California Los Angeles. Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years:. Associate Dean for Global Health. University of Alabama at Birmingham. Birmingham, Alabama. Cases from the Clinic(. ians. ): . Case. -based Panel Discussion. AU Final: 02/21/17. New York, New York: February 24, 2017.